Stock listing

Lang & Schwarz:A2QD9S Simcere Pharmaceutical Group Limited Aktie

German listing (Lang & Schwarz) of Simcere Pharmaceutical Group Limited · home listing HKEX:2096

Follow Simcere Pharmaceutical Group Limited into a list and get an email when it puts out news.

Home listing price · HKEX:2096

$10.19 HKD -0.23 (-2.2%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, HKEX:2096

Past year -22.6% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$10.14 – $10.42 HKDNov 20, 2026
Volume
4.46M sharesNov 20, 2026
Market cap
$26.05B HKDAt the close on Nov 20, 2026 · price × 2.56B shares outstanding
52-week range
$9.07 – $14.34 HKDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$54.70M HKDMedian day 4.48M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Simcere Pharmaceutical Group Limited logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
HKEX:2096 · Home$10.19 HKD-0.23 (-2.2%)4,461,784$10.36$10.42$10.14$10.42Close on Nov 20, 2026
Frankfurt:S2P€1.19 EUR+0.01 (+0.8%)—€1.19€1.19€1.19€1.18Close on Nov 19, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · HKEX:2096 · HKD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$10.19-0.23-2.2%$10.36$10.42$10.144,461,784
$10.42-0.08-0.8%$10.40$10.58$10.343,989,407
$10.50-0.05-0.5%$10.67$10.67$10.333,883,000
$10.55-0.03-0.3%$10.49$10.63$10.423,077,000
$10.58-0.31-2.8%$10.71$10.85$10.512,365,537
$10.89-0.02-0.2%$10.81$11.03$10.772,500,600
$10.91-0.12-1.1%$11.15$11.15$10.713,201,000
$11.03-0.17-1.5%$11.20$11.33$10.992,523,540
$11.20+0.11+1.0%$11.30$11.38$11.132,085,603
$11.09-0.08-0.7%$11.00$11.32$10.874,433,060
$11.17+0.40+3.7%$10.84$11.29$10.845,637,000
$10.77+0.59+5.8%$10.20$10.82$10.178,272,519
$10.18+0.16+1.6%$10.11$10.22$9.9158,603,519
$10.02-0.12-1.2%$10.07$10.23$9.868,895,000
$10.14-0.24-2.3%$10.23$10.44$10.044,494,000
$10.38+0.07+0.7%$10.30$10.48$10.234,208,000
$10.31+0.12+1.2%$10.21$10.46$10.199,611,610
$10.19-0.32-3.0%$10.44$10.57$10.089,373,796
$10.51-0.18-1.7%$10.84$10.98$10.473,312,000
$10.69+0.31+3.0%$10.33$10.82$10.156,084,000
$10.38-0.49-4.5%$10.68$10.86$10.335,828,700
$10.87-0.07-0.6%$11.07$11.10$10.832,100,000
$10.94-0.08-0.7%$11.02$11.20$10.862,445,000
$11.02+0.19+1.8%$10.85$11.29$10.855,801,000
$10.83-0.05-0.5%$10.87$11.05$10.703,387,000
$10.88+0.16+1.5%$10.80$10.99$10.562,487,000
$10.72-0.18-1.7%$10.90$10.90$10.505,233,215
$10.90+0.01+0.1%$11.04$11.05$10.821,771,000
$10.89-0.09-0.8%$10.92$11.10$10.624,810,000
$10.98-0.42-3.7%$11.50$11.63$10.984,765,000
$11.40-0.13-1.1%$11.50$11.51$11.251,281,340
$11.53+0.12+1.1%$11.64$11.64$11.50983,718
$11.41-0.05-0.4%$11.27$11.44$11.111,992,000
$11.46-0.39-3.3%$11.80$11.80$11.212,432,000
$11.85+0.48+4.2%$11.25$11.89$11.258,006,844
$11.37+0.13+1.2%$11.19$11.49$11.193,446,000
$11.24+0.05+0.4%$11.18$11.48$11.182,795,000
$11.19-0.20-1.8%$11.30$11.30$11.05506,000
$11.39-0.28-2.4%$11.61$11.71$11.283,584,000
$11.67+0.07+0.6%$11.61$11.73$11.472,776,000
$11.60-0.01-0.1%$11.75$11.75$11.354,663,989
$11.61+0.44+3.9%$11.30$11.82$11.275,801,000
$11.17-0.10-0.9%$11.07$11.49$11.0712,393,000
$11.27+0.10+0.9%$11.06$11.36$11.022,608,472
$11.17-0.08-0.7%$11.11$11.25$11.062,716,666
$11.25-0.14-1.2%$11.38$11.50$11.162,323,000
$11.39+0.34+3.1%$11.07$11.44$10.927,211,232
$11.05-0.17-1.5%$11.17$11.20$10.937,763,000
$11.22-0.35-3.0%$11.57$11.57$11.135,096,000
$11.57-0.06-0.5%$11.64$11.68$11.463,367,000
$11.63+0.05+0.4%$11.60$11.76$11.462,111,000
$11.58-0.05-0.4%$11.70$11.74$11.424,869,000
$11.63-0.14-1.2%$11.77$12.01$11.594,919,000
$11.77-0.06-0.5%$11.88$11.90$11.476,869,000
$11.83+0.84+7.6%$11.52$11.87$11.1514,737,000
$10.99-0.11-1.0%$11.10$11.10$10.964,355,000
$11.10-0.20-1.8%$11.31$11.35$11.027,703,000
$11.30-0.21-1.8%$11.51$11.51$11.274,726,000
$11.51-0.09-0.8%$11.60$11.60$11.334,617,000
$11.60+0.07+0.6%$11.59$11.79$11.535,882,000
$11.53-0.07-0.6%$11.69$11.69$11.345,952,643
$11.60-0.48-4.0%$12.18$12.29$11.525,191,643
$12.08-0.12-1.0%$12.40$12.40$11.877,444,000
$12.20+0.03+0.2%$12.69$12.82$12.1314,074,000
Ticker
Lang & Schwarz:A2QD9S
Asset type
Stock
Sector
Health care
Industry
Pharmaceuticals
Exchange
Lang & Schwarz
Currency
EUR

What changed lately

Latest news

All Simcere Pharmaceutical Group Limited news

Simcere Pharmaceutical Group Limited on 6ix

Sector
Health care
Industry
Pharmaceuticals
News releases
26 in the last 12 months · 42 in all · newest Nov 20, 2026 · oldest 2021

Where Simcere Pharmaceutical Group Limited is listed

ListingExchangeCountryCurrency
HKEX:2096 先聲藥業 · Home listingHKEXHong KongHKD
OTC:SMHGFOTCUnited StatesUSD
LS Exchange:A2QD9SLS ExchangeGermanyEUR
gettex:S2PgettexGermanyEUR
Tradegate:S2PTradegateGermanyEUR
Dusseldorf:S2PDusseldorfGermanyEUR
Frankfurt:S2PFrankfurtGermanyEUR
Munich:S2PMunichGermanyEUR
Stuttgart:S2PStuttgartGermanyEUR
Lang & Schwarz:A2QD9S · This pageLang & SchwarzGermanyEUR

Valuation

P/E 16.5× against a median of 22.3×: 3rd lowest of 11 Pharmaceuticals companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026

Enterprise value
$24.15B HKD
P/E
16.5×
EV/sales
2.7×
EV/EBITDA
10.6×
Price/book
2.4×
Gross margin
81.6%
Operating margin
20.1%
Net margin
17.4%
Debt to equity
0.3×
Beta
No index for this market yet

Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Simcere Pharmaceutical Group Limited · HKEX:2096US$3.32BUS$3.08B16.5×2.7×10.6×2.4×17.4%0.3×n/a
China Resources Pharmaceutical Group Ltd. · HKEX:3320US$3.51BUS$14.02B5.2×0.3×5.1×0.4×1.5%1.9×n/a
Zhejiang Huahai Pharmaceutical Co., Ltd. Class A · SSE:600521US$3.49BUS$3.65B24.6×2.5×n/a2.3×9.8%0.3×n/a
Orion Oyj Class A · OMXHEX:ORNAVUS$3.42BUS$3.40B4.7×1.4×3.5×2.2×30.3%0.1×n/a
Jiangsu Nhwa Pharmaceutical Co., Ltd. Class A · SZSE:002262US$3.41BUS$2.79B20.8×3.0×n/a2.6×17.7%0.0×n/a
Beijing Tiantan Biological Products Corporation Limited Class A · SSE:600161US$3.39BUS$3.10B32.3×3.7×n/a1.9×12.6%0.0×n/a
Arcutis Biotherapeutics, Inc. · NASDAQ:ARQTUS$3.33BUS$3.18B111×6.3×85.1×13.7×5.9%0.5×1.38
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Class A · SSE:600329US$3.20BUS$3.00B23.9×4.3×n/a3.4×19.2%0.0×n/a
Virbac SA · EURONEXT:VIRPUS$3.15BUS$3.35B19.0×2.1×11.0×2.4×10.3%0.3×n/a
Tasly Pharmaceutical Group Co. Ltd. Class A · SSE:600535US$3.14BUS$2.60B17.1×2.2×n/a1.6×15.3%0.0×n/a
Hualan Biological Engineering Inc. Class A · SZSE:002007US$3.13BUS$2.62B35.6×4.6×n/a2.0×15.4%0.0×n/a
Median of the othersUS$3.36BUS$3.14B22.3×2.8×8.1×2.3×14.0%0.1×1.38

Forecasts

Analysts' consensus from EODHD, read Nov 11, 2026. Not 6ix's view and not investment advice.

Price target
19.49 HKD · Analysts' mean
EPS, year to Dec 2026
0.69 · 2 analysts
Revenue, year to Dec 2026
1.52B · 3 analysts

Team and board

Officers

OfficerRole
Tang RenhongNon-Executive Director of Simcere, Chairman of the Board and CEO of Simcere Zaiming
Shen JunChief Financial Officer and Secretary of the Board of Simcere Zaiming
Wan YushanExecutive Director and Chief Financial Officer
Felix WangSenior Vice President
Goh Aik HanSenior Vice President, Chief Medical Officer
Tamas OraveczSVP & CSO of Simcere Zaiming
Wang XiExecutive Director and Vice President
Wang YongyuSenior Vice President and Chief Medical Officer of Simcere Zaiming
Zhou GaoboChief Investment Officer

Board

DirectorRole
Ren JinshengChairman of Simcere Pharmaceutical Group
Tang RenhongNon-Executive Director of Simcere, Chairman of the Board and CEO of Simcere Zaiming
Wan YushanExecutive Director and Chief Financial Officer
Wang XiExecutive Director and Vice President

Events

Next results
Mar 22, 2027 (expected)
QuarterResultsShare move
Q2 2025Aug 21, 2025 · Before open+3.1%
Quarter to Mar 31, 2025Apr 28, 2025+2.3%
Q4 2024Mar 24, 2025 · Before open+0.5%
Q3 2024Nov 18, 2024−3.4%
Q2 2024Aug 21, 2024−4.9%
Q1 2024Jun 14, 2024 · Before open−0.5%
Q4 2023Mar 20, 2024+3.6%
Q3 2023Nov 16, 2023−2.1%
Q2 2023Aug 21, 2023 · Before open+0.2%
Q1 2023May 11, 2023−3.1%
All 19 quarters
QuarterResultsShare move
Q4 2022Mar 31, 2023 · Before open+0.7%
Q3 2022Nov 17, 2022+4.5%
Q2 2022Aug 31, 2022 · Before open−0.3%
Q1 2022May 12, 2022+19.1%
Q4 2021Mar 24, 2022 · Before open+0.9%
Q3 2021Nov 11, 2021−3.7%
Q2 2021Aug 26, 2021 · Before open−2.7%
Q1 2021May 6, 2021−1.8%
Q4 2020Mar 25, 2021 · Before open−1.3%

Open Events

Financials

Annual, in CNY

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2012
Revenue7.73B6.64B6.61B6.32B5.00B4.51B5.04B4.51B3.87B2.08B
Cost of revenue1.42B1.31B1.62B1.32B1.08B899.9M888.5M771.2M586.3M361.1M
Gross profit6.31B5.32B4.98B5.00B3.92B3.61B4.15B3.74B3.28B1.72B
Research and development1.56B1.41B1.56B1.73B1.42B1.14B716.4M447.1M212.3M228.7M
Selling, general and administrative599.3M526.0M487.8M444.2M382.5M411.5M142.6M129.7M126.9M256.0M
Operating income1.56B848.0M711.8M862.5M1.45B926.8M1.17B941.9M530.6M96.4M
Depreciation and amortization380.8M337.9M309.6M283.6M251.8M227.4M162.5M120.0M104.1M131.6M
EBITDA1.94B1.19B1.02B1.15B1.70B1.15B1.33B1.06B634.7M228.0M
Interest expense95.8M69.6M34.6M34.4M70.8M133.7M116.0M47.5M58.4M0
Income before tax1.51B819.9M740.0M888.2M1.40B805.1M1.08B929.0M497.3M-20.0M
Income tax170.3M86.7M26.1M-40.5M-97.1M140.8M78.2M195.4M146.9M5.58M
Net income1.34B733.2M714.8M930.9M1.51B669.5M1.00B733.7M350.4M57.0M
Earnings per share, basic0.540.290.270.360.580.260.390.280.130.53

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2012
Cash and equivalents3.55B1.94B2.01B1.66B973.1M3.27B354.8M1.19B572.6M178.2M
Short-term investments65.6M10.0M11.1M964.2M1.21B3.63M547.0M263.3M509.1M
Receivables2.96B2.71B2.64B2.50B2.40B1.87B1.34B1.65B1.24B1.09B
Inventory589.7M593.6M770.1M304.8M235.2M311.1M248.2M265.6M218.3M120.9M
Current assets7.39B5.47B5.64B5.45B4.98B6.47B2.90B3.67B2.78B1.74B
Property, plant and equipment2.53B2.27B2.17B2.14B1.93B2.13B1.87B1.38B1.18B840.6M
Goodwill142.5M142.5M142.5M172.8M172.8M172.8M142.5M142.5M142.5M284.6M
Total assets14.7B11.5B10.9B10.8B10.2B10.9B6.77B6.34B5.20B3.37B
Accounts payable240.6M275.7M317.2M335.4M324.0M242.1M254.9M307.6M215.1M62.1M
Current liabilities3.35B2.73B2.69B2.96B3.06B3.50B3.43B4.11B2.53B1.21B
Long-term debt7.48M8.25M205.8M001.28B1.14B78.0M297.5M
Total debt1.20B1.21B1.43B1.51B1.64B3.30B2.94B324.9M442.1M
Total liabilities5.31B4.44B3.63B3.64B3.70B5.61B5.29B4.77B3.42B1.30B
Shareholders' equity9.41B7.07B7.22B7.13B6.44B5.30B1.48B1.57B1.78B2.01B
Shares outstanding2.49B2.52B2.61B2.62B2.61B2.61B2.61B2.61B2.61B107.4M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2012
Cash from operations2.01B1.39B151.0M1.35B-202.0M96.7M772.8M775.8M939.1M313.6M
Capital spending-862.2M-762.6M-979.9M-678.0M-209.5M-352.8M-507.7M-335.2M-292.2M-73.3M
Free cash flow1.15B628.5M-828.8M676.7M-411.5M-256.1M265.1M440.6M646.9M240.2M
Cash from investing-1.33B-1.05B1.09B68.3M-435.5M529.1M-592.9M-472.4M-508.4M-65.6M
Cash from financing894.4M-407.4M-894.8M-753.7M-1.62B2.35B-1.01B311.3M-347.3M-279.6M
Dividends paid-390.7M-401.5M-419.2M-391.3M-391.3M-391.3M-912.1M-549.1M-549.1M
Share buybacks-74.3M-688.0M-289.1M003.12B-121.9M
Change in cash1.56B-64.1M348.9M684.5M-2.30B2.92B-832.8M615.1M83.3M-31.7M

Open Financials

Filings

FilingDateTypeFiled with
Next Day Disclosure ReturnNov 20, 2026Next day disclosure returnHKEX
Next Day Disclosure ReturnNov 18, 2026Next day disclosure returnHKEX
Next Day Disclosure ReturnNov 17, 2026Next day disclosure returnHKEX
VOLUNTARY ANNOUNCEMENT - THE CLINICAL TRIAL APPROVAL FOR SIM0712 (STAT6) ISSUED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATIONNov 16, 2026Operations updateHKEX
VOLUNTARY ANNOUNCEMENT - INCLUSION OF SANBEXIN SUBLINGUAL TABLETS INTO THE NEW NATIONAL REIMBURSEMENT DRUG LISTNov 15, 2026Other filingsHKEX
Next Day Disclosure ReturnNov 11, 2026Next day disclosure returnHKEX
VOLUNTARY ANNOUNCEMENT - THE CLINICAL TRIAL APPROVAL FOR SIM0725 (CD122) ISSUED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATIONNov 10, 2026Other filingsHKEX
VOLUNTARY ANNOUNCEMENT - THE CLINICAL TRIAL APPROVAL FOR SIM0709 (TL1A/IL-23P19 BISPECIFIC ANTIBODY) ISSUED BY THE GERMAN REGULATORY AUTHORITY AND ETHICS COMMITTEENov 9, 2026Operations updateHKEX
VOLUNTARY ANNOUNCEMENT - NEW DRUG APPLICATION (NDA) OF ZEMPROCITINIB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS WAS ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATIONNov 5, 2026Operations updateHKEX
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026Nov 4, 2026Monthly returnHKEX
All 23 filings
FilingDateTypeFiled with
Next Day Disclosure ReturnNov 3, 2026Next day disclosure returnHKEX
VOLUNTARY ANNOUNCEMENT - ENTERING INTO AN EXCLUSIVE PROMOTION SERVICES AGREEMENT WITH LYNK PHARMACEUTICALS IN RESPECT OF DERMATOLOGICAL INDICATIONS OF ZEMPROCITINIBNov 2, 2026Other filingsHKEX
Next Day Disclosure ReturnOct 27, 2026Next day disclosure returnHKEX
Next Day Disclosure ReturnOct 26, 2026Next day disclosure returnHKEX
Next Day Disclosure ReturnOct 23, 2026Next day disclosure returnHKEX
Next Day Disclosure ReturnOct 22, 2026Next day disclosure returnHKEX
Next Day Disclosure ReturnOct 13, 2026Next day disclosure returnHKEX
Next Day Disclosure ReturnOct 9, 2026Next day disclosure returnHKEX
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026Oct 5, 2026Monthly returnHKEX
NOTIFICATION LETTER AND REPLY FORM TO NON-REGISTERED HOLDERS: NOTICE OF PUBLICATION OF INTERIM REPORT 2026Sep 24, 2026Notification letterHKEX
NOTIFICATION LETTER AND REPLY FORM TO REGISTERED SHAREHOLDERS: NOTICE OF PUBLICATION OF INTERIM REPORT 2026Sep 24, 2026Notification letterHKEX
2026 INTERIM REPORTSep 24, 2026Interim reportHKEX
(Revised) Next Day Disclosure ReturnSep 14, 2026Next day disclosure returnHKEX

Open Filings

Cap table

Built by 6ix from Simcere Pharmaceutical Group Limited’s releases

Common shares
2,556,369,618
Fully diluted
2,556,369,618

Fully diluted

LineShares
Common shares2,556,369,618

Share count over time

CountShares
Nov 22, 20262,556,369,618

Open Cap table

Shareholders

Register

HolderSharesOf the companyAs of
REN Jinsheng1.73B67.4%Jul 13, 2026
WANG Xi1.73B67.4%Jul 13, 2026
Fortune Fountain Investment Limited1.73B67.4%Jul 13, 2026
Simcere Holding Limited1.73B67.4%Jul 13, 2026
REN Yong1.73B67.4%Jul 13, 2026
Li Shimeng1.73B67.4%Jul 13, 2026
Ren Weidong1.73B67.4%Jul 13, 2026
P&H Holdings Group Ltd.1.73B67.4%Jul 13, 2026
Excel Investments Group Limited1.73B67.4%Jul 13, 2026
Simcere Investments Group Limited1.73B67.4%Jul 13, 2026
All 15 holders
HolderSharesOf the companyAs of
Ren Zhen1.73B67.4%Jul 13, 2026
Simcere Pharmaceutical Holding Limited1.73B67.4%Jul 13, 2026
Artking Global Limited1.73B67.4%Jul 13, 2026
Right Wealth Holdings Limited1.73B67.4%Jul 13, 2026
Peng Suqin1.73B67.4%Jul 13, 2026

Funds

HolderSharesValueAs of
Global Emerging Markets Fund19.6MUS$30.9MJul 31, 2026
Vanguard Total International Stock Index Fund12.4MUS$19.5MJul 31, 2026
Vanguard Emerging Markets Stock Index Fund12.2MUS$19.3MJul 31, 2026
iShares Core MSCI Emerging Markets ETF11.5MUS$14.7MMay 31, 2026
Avantis Emerging Markets Equity ETF6.23MUS$7.92MMay 31, 2026
Emerging Markets Core Equity 2 Portfolio4.71MUS$7.4MJul 31, 2026
Vanguard Ftse All-World Ex-Us Small-Cap Index Fund3.5MUS$5.51MJul 31, 2026
Siit World Equity Ex-Us Fund1.42MUS$1.8MMay 31, 2026
iShares Emerging Markets Equity Factor ETF1.39MUS$1.77MMay 31, 2026
The Emerging Markets Small Cap Series1.3MUS$2.04MJul 31, 2026
All 40 holders
HolderSharesValueAs of
Avantis Emerging Markets Value ETF1MUS$1.28MMay 31, 2026
Dimensional Emerging Markets Core Equity 2 ETF810KUS$1.28MJul 31, 2026
College Retirement Equities Fund - Total Global Stock Account658KUS$829KJun 30, 2026
Dimensional Emerging Core Equity Market ETF649KUS$1.02MJul 31, 2026
Vanguard Total World Stock Index Fund617KUS$971KJul 31, 2026
Dimensional World ex. U.S. Core Equity 2 ETF604KUS$951KJul 31, 2026
iShares Core MSCI Total International Stock ETF570KUS$897KJul 31, 2026
Multi-Manager International Equity Strategies Fund565KUS$719KMay 31, 2026
Fidelity Total International Index Fund555KUS$874KJul 31, 2026
Emerging Economies Fund475KUS$604KMay 31, 2026
WisdomTree China ex-State-Owned Enterprises Fund452KUS$568KJun 30, 2026
iShares MSCI China Small-Cap ETF378KUS$481KMay 31, 2026
World ex U.S. Core Equity Portfolio265KUS$417KJul 31, 2026
Avantis Emerging Markets Equity Fund259KUS$329KMay 31, 2026
Global Emerging Markets Account238KUS$300KJun 30, 2026
iShares MSCI Emerging Markets Small-Cap ETF208KUS$265KMay 31, 2026
State Street Global All Cap Equity ex-U.S. Index Portfolio178KUS$224KJun 30, 2026
Diversified Equity Alpha Master Portfolio174KUS$219KJun 30, 2026
Emerging Markets Social Core Equity Portfolio166KUS$261KJul 31, 2026
Vanguard ESG International Stock ETF164KUS$209KMay 31, 2026
State Street(R) SPDR(R) S&P(R) China ETF146KUS$183KJun 30, 2026
Dimensional Emerging Markets Sustainability Core 1 ETF119KUS$187KJul 31, 2026
Emerging Markets Sustainability Core 1 Portfolio94,000US$148KJul 31, 2026
Avantis Emerging Markets Small Cap Equity ETF85,000US$108KMay 31, 2026
Emerging Markets Targeted Value Portfolio84,000US$132KJul 31, 2026
World ex U.S. Targeted Value Portfolio43,000US$67,656Jul 31, 2026
Siit Screened World Equity Ex-Us Fund35,000US$44,521May 31, 2026
iShares Global Equity Factor ETF32,000US$50,348Jul 31, 2026
Wilshire International Equity Fund21,000US$26,456Jun 30, 2026
FlexShares Morningstar Emerging Markets Factor Tilt Index Fund19,000US$29,924Jul 31, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Felix WangSenior Vice President · Since at least Nov 5, 2026
Goh Aik HanSenior Vice President, Chief Medical Officer · Since at least Nov 5, 2026
Ren JinshengChairman of Simcere Pharmaceutical Group · Since at least Nov 5, 2026
Shen JunChief Financial Officer and Secretary of the Board of Simcere Zaiming · Since at least Nov 5, 2026
Tamas OraveczSVP & CSO of Simcere Zaiming · Since at least Nov 5, 2026
Tang RenhongNon-Executive Director of Simcere, Chairman of the Board and CEO of Simcere Zaiming · Since at least Nov 5, 2026
Wang XiExecutive Director and Vice President · Since at least Nov 5, 2026
Wang YongyuSenior Vice President and Chief Medical Officer of Simcere Zaiming · Since at least Nov 5, 2026
Wan YushanExecutive Director and Chief Financial Officer · Since at least Nov 5, 2026
Zhou GaoboChief Investment Officer · Since at least Jun 12, 2026

Open People

Log in to ask 6ix AI your own questions about Simcere Pharmaceutical Group Limited.